TMPRSS4 and gastric cancer: In terms of clinical stages, there was significant differences in OS and RFS of patients with stage III GC between the two groups (p=0.0064 and p=0.012, respectively): the 5-year OS rates of TMPRSS4-positive and TMPRSS4-negative groups were 38% and 85%, respectively, and the 5-year RFS rates of TMPRSS4-positive and TMPRSS4-negative group were 18% and 67%, respectively (Fig. 3a, b).